Morphic Holding, Inc. 31Y.F Stock
Morphic Holding, Inc. Price Chart
Morphic Holding, Inc. 31Y.F Financial and Trading Overview
| Morphic Holding, Inc. stock price | 29.2 EUR |
| Previous Close | 54.5 EUR |
| Open | 53.5 EUR |
| Bid | 53.5 EUR x N/A |
| Ask | 55 EUR x N/A |
| Day's Range | 53.5 - 53.5 EUR |
| 52 Week Range | 22.6 - 56.5 EUR |
| Volume | 18 EUR |
| Avg. Volume | 3 EUR |
| Market Cap | 2.45B EUR |
| Beta (5Y Monthly) | 1.145448 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.31 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 100.5 EUR |
31Y.F Valuation Measures
| Enterprise Value | 1.75B EUR |
| Trailing P/E | N/A |
| Forward P/E | -17.038216 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 35.558525 |
| Price/Book (mrq) | 4.9725814 |
| Enterprise Value/Revenue | 25.315 |
| Enterprise Value/EBITDA | -24.959 |
Trading Information
Morphic Holding, Inc. Stock Price History
| Beta (5Y Monthly) | 1.145448 |
| 52-Week Change | 78.57% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 56.5 EUR |
| 52 Week Low | 22.6 EUR |
| 50-Day Moving Average | 44.44 EUR |
| 200-Day Moving Average | 33.2 EUR |
31Y.F Share Statistics
| Avg. Volume (3 month) | 3 EUR |
| Avg. Daily Volume (10-Days) | 1 EUR |
| Shares Outstanding | 45.83M |
| Float | 28.74M |
| Short Ratio | N/A |
| % Held by Insiders | 18.88% |
| % Held by Institutions | 84.62% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -92.37% |
| Operating Margin (ttm) | -102.87% |
| Gross Margin | -53.81% |
| EBITDA Margin | -101.42% |
Management Effectiveness
| Return on Assets (ttm) | -10.56% |
| Return on Equity (ttm) | -17.21% |
Income Statement
| Revenue (ttm) | 68.95M EUR |
| Revenue Per Share (ttm) | 1.77 EUR |
| Quarterly Revenue Growth (yoy) | -78.10% |
| Gross Profit (ttm) | -31254000 EUR |
| EBITDA | -69930000 EUR |
| Net Income Avi to Common (ttm) | -63692000 EUR |
| Diluted EPS (ttm) | -1.45 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 421.28M EUR |
| Total Cash Per Share (mrq) | 10.61 EUR |
| Total Debt (mrq) | 3.48M EUR |
| Total Debt/Equity (mrq) | 0.82 EUR |
| Current Ratio (mrq) | 32.323 |
| Book Value Per Share (mrq) | 10.759 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -104283000 EUR |
| Levered Free Cash Flow (ttm) | -48465624 EUR |
Profile of Morphic Holding, Inc.
| Country | Germany |
| State | MA |
| City | Waltham |
| Address | 35 Gatehouse Drive, A2 |
| ZIP | 02451 |
| Phone | 781 996 0955 |
| Website | https://www.morphictx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 107 |
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Q&A For Morphic Holding, Inc. Stock
What is a current 31Y.F stock price?
Morphic Holding, Inc. 31Y.F stock price today per share is 29.2 EUR.
How to purchase Morphic Holding, Inc. stock?
You can buy 31Y.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Morphic Holding, Inc.?
The stock symbol or ticker of Morphic Holding, Inc. is 31Y.F.
Which industry does the Morphic Holding, Inc. company belong to?
The Morphic Holding, Inc. industry is Biotechnology.
How many shares does Morphic Holding, Inc. have in circulation?
The max supply of Morphic Holding, Inc. shares is 50.09M.
What is Morphic Holding, Inc. Price to Earnings Ratio (PE Ratio)?
Morphic Holding, Inc. PE Ratio is now.
What was Morphic Holding, Inc. earnings per share over the trailing 12 months (TTM)?
Morphic Holding, Inc. EPS is -3.31 EUR over the trailing 12 months.
Which sector does the Morphic Holding, Inc. company belong to?
The Morphic Holding, Inc. sector is Healthcare.